Add BrightSurf on Google Email

The molecular underpinnings of T cell exhaustion

Scientists at La Jolla Institute for Immunology have discovered that exhausted T cells have distinct DNA structures and activate specific genes, including NFAT and Nr4a proteins. These findings provide new insights into the molecular underpinnings of T cell exhaustion and offer potential targets for improving cancer immunotherapies.

SourceLa Jolla Institute for Immunology·JournalProceedings of the National Academy of Sciences·DateMar 14, 2017

Immunotherapy trial cures Tasmanian devils of DFTD

An international study has shown that immunotherapy can cure Tasmanian devils of the deadly devil facial tumour disease (DFTD). The treatment successfully triggered the devil's immune system to recognise and destroy established DFTD tumours, with tumours shrinking and disappearing over three months.

SourceUniversity of Tasmania·JournalScientific Reports·DateMar 9, 2017

Oral immunotherapy is safe, effective for peanut-allergic preschoolers, study suggests

A clinical trial found that oral immunotherapy is safe and effective for peanut-allergic preschool children, with over 80% successfully introducing peanut into their diets. The treatment involved gradually increasing amounts of peanut protein daily and was comparable in effectiveness between low-dose and high-dose regimens.

SourceNIH/National Institute of Allergy and Infectious Diseases·JournalJournal of Allergy and Clinical Immunology·DateAug 10, 2016

NIH-funded study suggests potential to predict peanut allergy immunotherapy outcomes

A new NIH-funded study suggests that changes in immune cell subtypes after oral immunotherapy for peanut allergy can help predict treatment success. The research, published in Proceedings of the National Academy of Sciences, found a novel T-cell population that likely would not mount an allergic response expanded with treatment.

SourceNIH/National Institute of Allergy and Infectious Diseases·JournalProceedings of the National Academy of Sciences·DateJan 25, 2016

Autoimmune cerebellar ataxia

A Mayo Clinic study found that nearly three-quarters of patients with autoimmune cerebellar ataxia were women. The median duration from symptom onset to last follow-up was 25 months, with 51 patients experiencing physician-reported neurologic improvement with immunotherapy and cancer therapy.

SourceMayo Clinic·JournalJAMA Neurology·DateSep 29, 2015

Ludwig Cancer Research and the Cancer Research Institute evaluate immunotherapeutic strategies for brain cancer and other types of solid tumors

Ludwig Cancer Research and the Cancer Research Institute launched clinical trials to evaluate immunotherapeutic strategies for brain cancer and various solid tumors. The trials will test MedImmune's checkpoint blockade antibody durvalumab in patients with glioblastoma multiforme, a deadly form of adult brain cancer.

State-of-the-science help for hay fever sufferers

Hay fever sufferers can benefit from state-of-the-science treatments like sublingual immunotherapy. The American Academy of Otolaryngology recommends this treatment for patients with specific allergies who don't respond to other treatments, with a completion period of up to five years. Other key recommendations include diagnosing and t...